Latest News: Treatments & Research

Appraisal of risdiplam in Scotland delayed further

03 August 2021 / Posted in: Treatments & Research

SMA UK, MDUK and TreatSMA have today written to the Scottish Medicines Consortium (SMC) to raise their concerns about the further delays with processing Roche’s submission for risdiplam.

Read full story

Data for Evrysdi Published in NEJM shows Significant Improvement in Survival and Motor Milestones in Babies with SMA Type 1

30 July 2021 / Posted in: Treatments & Research

The study, evaluating the efficacy and safety of Evrysdi™ (risdiplam) in babies aged 1-7 months old with symptomatic SMA Type 1, met its primary endpoint with 29% of infants sitting without support for at least five seconds by month 12 - a milestone not seen in the natural course of the condition.

Read full story

Community Update: Novartis Discontinues Development of Branaplam

21 July 2021 / Posted in: Treatments & Research

Novartis have confirmed that they've made the difficult decision to discontinue the development of branaplam (also known as LMI070) for the treatment of SMA. They explain that their decision was "made as the result of rapid advancements in the SMA treatment landscape in recent years."

Read full story

JCVI Issues Advice on COVID-19 Vaccination of Children and Young People

20 July 2021 / Posted in: Information, Treatments & Research, Support

The JCVI has looked at the available evidence around vaccinating children and young people under the age of 18. They have now advised that children at increased risk of serious COVID-19 disease are offered the Pfizer-BioNTech vaccine. That includes children aged 12 to 15 with severe neurodisabilities, Down’s syndrome, immunosuppression and multiple or severe learning disabilities.

Read full story

NHS England and NHS Improvement: UK Framework Action Plan Discussion

09 July 2021 / Posted in: Information, Treatments & Research

Since the publishing of The UK Rare Disease Framework on 9th January 2021, NHS England and NHS Improvement have been busy developing an Action Plan. Now, they and Findacure invite you to share your thoughts in a two-hour session on Tuesday 20th July.

Read full story

Apitegromab Receives Fast Track Designation in the US

07 July 2021 / Posted in: Treatments & Research

Apitegromab (also known as SRK-015) is a muscle-directed therapy that aims to reverse or restrict the muscle atrophy and weakness experienced by people living with SMA. Fast Track status is granted to drugs that show considerable potential for being able to treat life-threatening conditions that have limited therapeutic options.

Read full story

NICE’s Guidance for NHS-Funded Access to Zolgensma Published

07 July 2021 / Posted in: Treatments & Research

Today, NICE’s recommendations for NHS-funded access to Zolgensma that were first announced in March, have now been published and finalised. These will continue to run in parallel to the additional agreement also made in March by NHS England. Thanks to the many stakeholders who have got us to this positive place.

Read full story

Sign the Petition to Introduce Newborn Screening for SMA in the UK

25 June 2021 / Posted in: Information, Treatments & Research

SMA UK is a member of the UK SMA Newborn Screening Alliance which brings together patient groups, clinicians and many other stakeholders determined to see newborn screening for SMA introduced as part of the heel prick blood test in the UK. Show your support for our work and the work of the UK SMA Newborn Screening Alliance by signing the petition.

Read full story

UK SMA Patient Registry Update - June 2021

25 June 2021 / Posted in: Treatments & Research

The UK SMA Patient Registry collects clinical and genetic information from individuals with Spinal Muscular Atrophy. Patient Registry Project Manager, Lindsay Murphy, has put together an update on the latest figures and updates about the registry.

Read full story

SMA UK and Many Others Respond to NICE’s Consultation on Access to Risdiplam

23 June 2021 / Posted in: Treatments & Research

Our thanks to the many people we talked with who planned to make their own personal responses. These will powerfully echo the voices of those who responded to our surveys and spoke up at the committee meeting. Together, we are calling for access for all for whom risdiplam is a clinically safe option.

Read full story